65,437 trials
Pneumococcal Infection
Primary: Percentage of Participants With Solicited Injection-site Adverse Events (AEs) — 5.4; 6.3; 15.5; 13.0 Percentage of participants
Sickle Cell Disease
Primary: Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) — 1; 3; 1; 0 Participants
Migraine
Primary: Percentage of Participants Achieving at Least a 50% Reduction From Baseline in Mean MMDs Over Months 4, 5, and 6 in Relation to mPRS — 54.9 percentage of participants…
COVID-19 · Children With Medical Complexity (CMC)
Primary: Change in Protocol Uptake: Number of Participants Consented Compared to Number of Participants Approached — 51; 33 Caregiver/child dyads
Insomnia · Alcohol Use, Unspecified · Marijuana Use
Primary: Insomnia Severity Index (ISI) — 8.48; 9.69; 11.31; 7.14 Score on a scale — p=.004
Candidiasis, Chronic Mucocutaneous
Primary: Clinical Response to Treatment of Mucocutaneous Candidiasis — 4 Participants
Dry Eye
Primary: Number of Patients Reaching a Value of Schirmer I Test (Without Anaesthesia) >10mm/5min at Week 4 — 19; 2 Participants — p=<0.001
Metastatic Colon Cancer · Solid Tumor
Primary: Phase 1: Determine the Maximum Tolerated Dose of Poly-ICLC That Can be Combined With Pembrolizumab — 2 mg
Metastatic Breast Cancer
Primary: Overall Survival (OS) in Postmenopausal Female or Male Participants With Metastatic Breast Cancer — 49.1; 43.2 Months — p=<0.0001
Resident Knowledge and Attitudes Regarding Cross-cultural Care · Interpersonal and Communication Skills in Patient-clinician Encounters · Patient-reported Satisfaction With Resident Physicians Involved in Their Care
Primary: Change in Residents' Questionnaire Scores Measuring Knowledge From Pre- to Post-PACTS Curriculum — 74.3; 71.7 score on a scale — p=0.2422
Covid19
Primary: Part 1: Maximum Observed Serum Concentration (Cmax) of Sotrovimab Through Day 29 — 238.32; 188.66 Micrograms per milliliter
Hepatitis C
Primary: Community Pharmacy Program Successful Linkage — 38 Participants
Trypanosomiasis, African · Sleeping Sickness · Trypanosomiasis; Gambian
Primary: Percentage of Participants Whose Treatment Outcome at Month 18 is a Success — 93.1 percentage of participants
COVID19
Primary: Number of Participants With Inflammatory Marker Reduction of at Least 50% at Any Efficacy Time Point — 5; 8 Participants — p=0.16
Residential Characteristics · Emotions · Stress, Psychological
Primary: Emotional Response — 3.65; 4.31; 1.29; 0.33 units on a scale